Intervacc AB (publ) (FRA:2E9)
Germany · Delayed Price · Currency is EUR 0.0361
+0.0002 (0.56%)
At close: Nov 28, 2025
Intervacc AB Company Description
Intervacc AB (publ) develops novel veterinary vaccines for animals in Sweden.
The company’s product pipeline includes Stangvac, a vaccine against equine strangles for horses; INV274, antigens for a vaccine against streptococcus suis for the treatment of weaned piglets; and INV412, a multi-component vaccine to protect against several bacteria which cause mastitis for treating cows.
It also engages in marketing and distribution of veterinary products in the Nordic markets, which includes vaccines and pharmaceuticals for swine, horses, cattle, and sheep.
The company was incorporated in 1983 and is based in Hägersten, Sweden.
Intervacc AB (publ)
| Country | Sweden |
| Founded | 1983 |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 15 |
| CEO | Jonas Sohlman |
Contact Details
Address: Västertorpsvägen 135 Hägersten, 129 44 Sweden | |
| Phone | 46 8 12 01 06 00 |
| Website | intervacc.se |
Stock Details
| Ticker Symbol | 2E9 |
| Exchange | Frankfurt Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | SEK |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Jonas Sohlman | Chief Executive Officer |
| Jan Persson | Chief Financial Officer |